Latest News
Keros Therapeutics, Inc.
- Keros Therapeutics, Inc. Estimates – NASDAQ:KROS
- Keros Therapeutics at Chardan conference: reset turns to pipeline data By Investing.com
- Keros Therapeutics Drops To US$10.66, Yet Insiders May Have Sold Too Early
- Keros Therapeutics Stock Price Forecast. Should You Buy KROS?
- Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen
- Keros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in Play
- Keros Therapeutics Enrolls First Patient in Phase 2 Rinvatercept DMD Trial
- Keros Therapeutics to receive $20M milestone from Takeda
- Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Headlines from the last 30 days, linking to the original publishers. See all market news →